timothy sykes logo
RARE Stock Crashes As Ultragenyx Faces GTX-102 Trial Failure Thumbnail
G Google News

RARE Stock Crashes As Ultragenyx Faces GTX-102 Trial Failure

TIM SYKES•UPDATED SEP. 4, 2026, 4:08 PM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

Ultragenyx Pharmaceutical Inc. stocks have been trading up by 3.03 percent following bullish sentiment on its rare-disease pipeline.

What Traders Need To Know

  • Gene therapy Genglycos (DTX401) won accelerated FDA approval with a Priority Review Voucher and a $2.7M list price, as the first therapy targeting GSDIa’s root cause.
  • Ninety-six-week Phase 3 data for Genglycos showed a 61% cut in daily cornstarch intake, stable glycemic control, and many patients dropping nighttime dosing with manageable safety.
  • Major banks including BofA, Morgan Stanley, Wells Fargo, and JPMorgan recently raised targets on Ultragenyx Pharmaceutical Inc. and stayed Buy/Overweight on the Genglycos and pipeline story.
  • GTX-102 Aspire in Angelman syndrome failed primary and secondary endpoints, driving sharp target cuts from Citi and H.C. Wainwright, though both kept Buy ratings and reset models.
  • Shares of RARE plunged 44.6% intraday to $14.70, while Wedbush trimmed its target and William Blair downgraded, even as the mean Street target near $33.95 signals upside from the selloff.

Candlestick Chart

Weekly Update Aug 31 – Sep 04, 2026: On Friday, September 04, 2026 Ultragenyx Pharmaceutical Inc. stock [NASDAQ: RARE] is trending up by 3.03%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – neutral

Ultragenyx (RARE) remains a high‑risk, late‑stage rare‑disease platform with improving top line but structurally weak fundamentals. Revenue of ~$673M with 21% three‑year CAGR and 87.8% gross margin demonstrates strong pricing power, yet EBIT margin of -79% and ROA around -46% highlight an unsustainable burn. Q2’26 operating cash outflow of $97M and negative equity (retained losses >$4.8B) underscore heavy cumulative cash consumption, despite a still‑adequate $292M cash and investments and no long‑term debt.

Technically, RARE has shifted from a stable mid‑20s consolidation to a breakdown-driven downtrend after the GTX‑102 failure. The collapse from ~$25.5 to the mid‑teens on extreme volume signals institutional capitulation, with 14.90–15.20 emerging as immediate support from the post‑gap intraday base. Short‑term, any rebound toward $18–19 should be sold; actionable level: initiate or add short/underweight against $19 resistance with a stop above $20, targeting a retest of $14.

Catalysts skew negative near term. While Genglycos’ accelerated approval and strong data validate Ultragenyx’s gene therapy capabilities, the failed GTX‑102 Aspire study removes a key value driver and justifies the sharp derating. Sector benchmarks (broader biotech and HC indices) are far less loss‑making and less binary‑event‑driven. Despite still‑bullish average Street targets in the low‑30s, recent PT cuts to $23–28 and $25, plus 45% share drawdown, argue for a Neutral stance with trading range $14–22 and structural resistance near $25.

More Breaking News

Quick Financial Overview

Ultragenyx Pharmaceutical Inc. is in classic high-beta biotech territory: strong revenue growth but deeply negative earnings and cash burn. The latest report shows $214M in quarterly revenue and about $673M over the trailing year, with gross margin near 87.8%, but profit margins are strongly negative and return on assets is around -43% to -46%. Operating cash flow at roughly -$97M for the quarter and net income of -$92M underscore that RARE is still funding an aggressive R&D and launch agenda, not self-funding growth.

On the balance sheet, Ultragenyx Pharmaceutical Inc. holds about $140M in cash at period end against total assets of $1.26B and negative equity of roughly -$291M, with a current ratio of 1.7 suggesting near-term liquidity is adequate but not lazy. The enterprise value near $1.17B and price-to-sales around 3.65 place RARE in the mid-cap biotech bucket where pipeline perception can swing the multiple fast. There is no dividend, so traders are paid only in price movement.

The chart shows exactly that volatility. RARE traded near $25.31 on 2026/08/31 and held around $25.51 on 2026/09/01 before collapsing to a $15.16 close on 2026/09/02 and grinding near $14.90–$15.25 in the following days. Intraday, the 5-minute tape around the latest session shows a tight range between roughly $15.0 and $16.1 with clear liquidity and responsive two-way flow, a typical post-capitulation equilibrium zone that traders can work around defined intraday levels.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”